Skip to content
aiqbench takeQuantum Computing

aiqbench analysis

This research demonstrates how quantum generative models can outperform classical baselines in creating high-fidelity synthetic patient data for rare diseases like Myelodysplastic Syndrome, addressing the critical challenge of scarce training datasets. By leveraging asymmetric databases on superconducting hardware, the study establishes a viable pipeline for enhancing in silico clinical trials where traditional methods struggle with limited samples. The results suggest that quantum approaches offer superior generalization and expressivity metrics specifically when data availability is constrained.
Source coveringarXiv
What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

A quantum generative model for in silico clinical trials using scarce training datasets

arXiv2 min read

arXiv:2608.28168v1 Announce Type: new Abstract: In silico methods have emerged as a strategy to complement clinical trials. These are particularly relevant for rare or heterogeneous diseases for which traditional methods are costly or difficult to apply. While classical generative models have shown an extremely good ability to generate high fidelity data when trained using extensive databases, they often struggle when the available samples for training are scarce. In this work, we leverage the potential of quantum computers to represent complex probability distributions to generate high fidelity in silico patients. We propose a pipeline able to combine asymmetric databases into a quantum circuit that serves as a quantum generative model. We evaluate the efficacy of our proposal using a database of Myelodysplastic Syndrome (MDS) patients with 7 clinical variables as a proof-of-concept. We executed our quantum generative model in the IBM Heron r2 ``ibm\_basquecountry'' superconducting quantum computer and compare our method with well known classical baselines. Our results show that the quantum generative model surpasses the classical generative models in generalization and expressivity metrics, indicating its potential validity to generate high fidelity in silico patients for clinical trials.

Abstract:In silico methods have emerged as a strategy to complement clinical trials. These are particularly relevant for rare or heterogeneous diseases for which traditional methods are costly or difficult to apply. While classical generative models have shown an extremely good ability to generate high fidelity data when trained using extensive databases, they often struggle when the available samples for training are scarce. In this work, we leverage the potential of quantum computers to represent complex probability distributions to generate high fidelity in silico patients. We propose a pipeline able to combine asymmetric databases into a quantum circuit that serves as a quantum generative model. We evaluate the efficacy of our proposal using a database of Myelodysplastic Syndrome (MDS) patients with 7 clinical variables as a proof-of-concept. We executed our quantum generative model in the IBM Heron r2 ``ibm\_basquecountry'' superconducting quantum computer and compare our method with well known classical baselines. Our results show that the quantum generative model surpasses the classical generative models in generalization and expressivity metrics, indicating its potential validity to generate high fidelity in silico patients for clinical trials.

arXiv:2608.28168 [quant-ph]

(or arXiv:2608.28168v1 [quant-ph] for this version)

https://doi.org/10.48550/arXiv.2608.28168 Focus to learn more arXiv-issued DOI via DataCite (pending registration)

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

Full text under the publisher's open licence · 273 words

Related coverage